Resverlogix Corp

RFS

Company Profile

  • Business description

    Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

  • Contact

    4820 Richard Road South West
    Suite 300
    CalgaryABT3E 6L1
    CAN

    T: +1 403 254-9252

    E: [email protected]

    https://www.resverlogix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    18

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,859.4192.701.19%
DAX 4024,445.24238.330.98%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,874.0919.910.22%
HKSE23,892.32255.75-1.06%
NASDAQ20,418.465.950.03%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers